Dermatology
| Psoriasis
Dermatology
Psoriasis

Secukinumab treatment results in improvements in DLQI associated with low absolute PASI scores: 24-month follow-up from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

book_2 Source: EADV Virtual - Poster session
calendar_today Published on Medfyle: November 2020
headphones 4 min

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Key messages

  • Secukinumab is a fully human monoclonal antibody targeting IL-17A.
  • This retrospective analysis evaluated 1,679 patients enrolled in BADBIR and receiving secukinumab; of these, 69.8% were biologic-naïve.
  • Over 24 months, secukinumab demonstrated improvement in absolute PASI and quality of life.
  • There was a difference in the correlation of DLQI with clinical outcomes between biologic-naïve and -experienced patients, suggesting increased expectations in later lines of treatment.
Presenting Author
Read more arrow_downward Hide arrow_upward

A. Bewley, MD
Whipps Cross and Royal London Hospitals, Barts Health NHS Trust, London UK


Feedback